A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life compared with a placebo, making it one of the first medications to show meaningful benefits for this disabling condition.
Source: Science Daily — This article was automatically imported from the source. Read full article at original source →
